Humana Eases Investor Fears With Q3 Earnings, Approaches Future With Caution
-
Nov 01, 2024
Humana’s third-quarter 2024 earnings results were better than many analysts feared, driven by higher-than-expected Medicare Advantage (MA) revenue and outperformance of the company’s CenterWell clinics.
For the quarter ending Sept. 30, Humana reported adjusted earnings per share (EPS) of $4.16, beating Wall Street’s consensus estimate of $3.42. The company’s consolidated medical loss ratio (MLR) of 89.8% was in line with the consensus estimate. During an Oct. 30 conference call to discuss quarterly earnings, CEO Jim Rechtin noted that the company slightly improved its 2024 EPS outlook from “approximately” $16.00 to “at least” $16.00. This was in sharp contrast to the company’s second-quarter release, which saw the company’s stock tumble more than 10% on the news of higher-than-anticipated inpatient admissions and the company not raising its full-year guidance.
Read more
© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.